Semaglutide applied to the treatment of obesity: clinical perspectives in the literature
DOI:
https://doi.org/10.33448/rsd-v12i9.43295Keywords:
Obesity; Glucagon-Like Peptide-1 Receptor; Drug therapy.Abstract
Obesity is a chronic disease defined by an excessive concentration of body fat, which has been affecting more than 1 billion individuals worldwide. This disease is usually related to other metabolic disorders, such as type 2 diabetes (DM2), cardiovascular diseases (CVD), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), in addition to some types of cancer. In this perspective, this work aims to analyze studies involving Semaglutide as an anti-obesity agent, since the use of Glucagon-like peptide-1 receptor (GLP-1 RA) agonists are being indicated as one of the most positive procedures in the treatment of obesity. A systematic literature review was carried out based on articles published in the Databases Pubmed, Lilacs, Acervo +, Dove Press and in the Revista Research, Development and Society, from July 2022 to July 2023. After the filters, 41 articles remained, from which titles and abstracts were analyzed, excluding those that did not deal with the clinical perspective of the use of Semaglutide for the treatment of obesity. The 21 selected articles were submitted to a complete reading, looking for convergences and divergences in the observed results. Most articles (20) demonstrated the efficacy of semaglutide and an acceptable safety profile for its use, associated with combined and specific therapy for each patient. No increased risk from adverse effects has been reported. Semaglutide is characterized as a promising alternative in the treatment of obesity, proving to be effective in significantly reducing body weight in a sustained manner.
References
Aldawsari, M. et al. (2023). The efficacy of GLP-1 Analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Dove Medical Press, 16: 575-595.
Alorfi, N. M. & Algarni, A. S. (2022). Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: a review. Clinical Pharmacology, 14: 61-67.
Anam, M. et al. (2022). Efficacy of Semaglutide in treating obesity: a systematic review of Randomized Controlled Trials (RCTs). Cureus, 14(12): e32610.
Bailey, C. J. et al. (2023). An update on peptide-based therapies for type 2 diabetes and obesity. Peptides, 161: 170939.
Bergmann, N. C. et al. (2023). Semaglutide for the treatment of overweight and obesity: a review. Diabetes, Obesity and Metabolism, 25(1): 18-35.
Berkovic, M. C. & Strollo F. (2023). Semaglutide-eye-catching results. World Journal of Diabetes, 14(4): 424-434.
Botelho, L. L. R.; Cunha, C. C. de A. & Macedo, M. (2011). O método da revisão integrativa nos estudos organizacionais. Gestão e Sociedade. Belo Horizonte, 5(11): 121-136.
Brasil. Agência Nacional de Vigilância Sanitária (2023). Wegovy (semaglutida). https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/wegovy-semaglutida.
Chao, A. M. et al. (2022). Clinical insight on Semaglutide for chronic weight management in adults: patient selection and special considerations. Drug Design, Development and Therapy, 16: 4449-4461.
Fornes, A. et al. (2022). Once-weekly Semaglutide for weight management: a clinical review. Journal of Pharmacy Technology, 38(4): 239-246.
Gomes, H. K. B. C. & Trevisan M. (2021). O uso do Ozempic (Semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Artigos.com, 29: e7498.
Haddad, F. et al. (2023). A comprehensive review on weight loss associated with anti-diabetic medications. Life - Multidisciplinar Digital Publishing Institute (MDPI), 13(4): 1012.
Kennedy, C. et al. (2023). The effect of Semaglutide on blood pressure in patients without Diabetes: a systematic review and meta-analysis. Journal of Clinical Medicine, 12(3): 772.
Kyriakidou, A. et al. (2022). Clinical and egnetic predictors of glycemic control and weight loss response to Liraglutide in patients with type 2 Diabetes. Journal of Personalized Medicine, 12: 424.
Lin X. & Li H. (2021). Obesity: epidemiology, pathophysiology, and therapeutics. Frontiers in Endocrinology, 12: 706978.
Meouchy, P. E. et al. Hypertension related to obesity: pathogenesis, characteristics and factors for control. International Journal of Molecular Sciences, 2022; 23(20): 12305.
Montalvan, D. E. A. et al. (2022). Relación entre el fármaco semaglutida y la reducción de peso en pacientes con obesidad: una revisión sistemática. Vive Revista de Salud, 5(15), 698-714.
Oliveira, I. P. et al. (2023). Semaglutida no tratamento de obesidade e sobrepeso. Research, Society and Development, 12(3): e29812340656.
OMS. Consulta da OMS sobre Obesidade (1999: Genebra, Suíça) e Organização Mundial da Saúde. (2000). Obesidade: prevenção e gestão da epidemia global: relatório de uma consulta da OMS. https://apps.who.int/iris/handle/10665/42330.
Popoviciu, M. S. et al. (2023). Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Jornal Internacional de Ciências Moleculares - Multidisciplinar Digital Publishing Institute (MDPI), 24(13): 10449.
Reis, J. R. C. et al. (2022). A prescrição de Peptídeo Semelhante a Glucagon 1 (GLP-1) no tratamento de pacientes portadores de diabetes tipo 2 e obesidade: uma revisão de literatura. Acervo Médico, 11: e10289.
Smith, I. et al. (2022). Semaglutide 2.4mg for the management of overweight and obesity: systematic literature review and meta-analysis. Diabetes, Metabolic Syndrome and Obesity, 15: 3961-3987.
Weghuber, D. et al. (2023). Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study. Journal of Comparative Effectiveness Research, 12(2): e220187.
Williams, D. M. et al. (2022). Glucagon-like Peptide-1 receptor analogues for the treatment of obesity. touchREVIEWS in Endocrinology, 18(1): 43-48.
World Obesity Federation. World Obesity Atlas 2023. https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023.
Xie, Z. et al. (2022). Efficacy and safety of Liraglutide and Semaglutide on weight loss in people with obesity or overweight: a systematic review. Clinical Epidemiology, 14: 1463-1476.
Xu, D. et al. (2022). Potential roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in nondiabetic populations. Cardiovascular Therapeutics, 6820377.
Yang, M. et al. (2022). The related metabolic diseases and treatments of obesity. Healthcare (Basel), 10(9): 1616.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Maria Carolina Alves Zanatta; Fabiana Sambini da Rocha; Tarcísia Alves Sambini Fumagali; Gabriela Aline Backes; Thalita Brambilla Sambini; Isadora Scremin Matsukuma; Gabriella Abdallah Martinez ; Aline Talwany Simões Benedetti; Letícia Augusto Pereira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
